Favorable outcomes of interferon-α and ribavirin treatment for a male with subacute sclerosing panencephalitis.
Antiviral Agents
/ administration & dosage
Drug Therapy, Combination
Humans
Infant
Interferon-alpha
/ administration & dosage
Male
Measles
/ complications
Measles virus
/ isolation & purification
Remission Induction
Ribavirin
/ administration & dosage
Subacute Sclerosing Panencephalitis
/ diagnostic imaging
Treatment Outcome
Young Adult
Acquired immunity
And T helper 17 lymphocytes (Th17)
Exome sequencing
Innate immunity
Interferon-α
Measles virus
Ribavirin
Subacute sclerosing panencephalitis (SSPE)
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 09 2021
15 09 2021
Historique:
received:
15
03
2021
revised:
21
06
2021
accepted:
05
07
2021
pubmed:
26
7
2021
medline:
24
12
2021
entrez:
25
7
2021
Statut:
ppublish
Résumé
Subacute sclerosing panencephalitis (SSPE) is a slow virus infection associated with mutant measles virus (MeV). The long-term outcome of antiviral treatments remains to be determined. We herein present a Japanese boy who was diagnosed with SSPE at 10 years of age. Intraventricular infusions of interferon-α effectively prevented the progress of symptoms during 14 years of follow-up period. Flow-cytometric analysis demonstrated higher proportion of T helper 17 cells (Th17, 18.2%) than healthy controls (4.8-14.5%) despite the normal subpopulation of peripheral lymphocytes. These data suggest that a group of patients with SSPE may show favorable responses to intraventricular infusions of interferon-α.
Identifiants
pubmed: 34304142
pii: S0165-5728(21)00183-1
doi: 10.1016/j.jneuroim.2021.577656
pii:
doi:
Substances chimiques
Antiviral Agents
0
Interferon-alpha
0
Ribavirin
49717AWG6K
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
577656Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.